Last reviewed · How we verify
Actemra®
At a glance
| Generic name | Actemra® |
|---|---|
| Also known as | Tocilizumab, tocilizumab, RoActemra |
| Sponsor | AO GENERIUM |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma (PHASE2)
- Treatment Tapering in JIA With Inactive Disease (PHASE3)
- A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma (PHASE1, PHASE2)
- Tocilizumab in Cardiac Transplantation (PHASE2)
- Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study (PHASE2)
- Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (PHASE2, PHASE3)
- A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis
- Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Actemra® CI brief — competitive landscape report
- Actemra® updates RSS · CI watch RSS
- AO GENERIUM portfolio CI